Medicamen Biotech Ltd - Stock Valuation and Financial Performance

BSE: 531146 | NSE: MEDICAMEQ | Pharmaceuticals & Drugs | Small Cap

Medicamen Biotech Share Price

484.55 16.90 3.61%
as on 12-Jul'24 16:01

DeciZen - make an informed investing decision on Medicamen Biotech

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat Undervalued

3. Price Trend

Semi Strong

Medicamen Biotech stock performance -

mw4me loader
P/E Ratio (SA):
46.83
Market Cap:
622.8 Cr.
52-wk low:
356.8
52-wk high:
903.5

Is Medicamen Biotech Ltd an attractive stock to invest in?

1. Is Medicamen Biotech Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Medicamen Biotech Ltd is a below average quality company.

2. Is Medicamen Biotech Ltd undervalued or overvalued?

The key valuation ratios of Medicamen Biotech Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

3. Is Medicamen Biotech Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Medicamen Biotech Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Medicamen Biotech:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Medicamen Biotech Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 8.5%7.8%6.9%18.2%16.4%12%10.3%9.2%9.3%8.3%-
Value Creation
Index
-0.4-0.5-0.50.30.2-0.1-0.3-0.3-0.3-0.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 73.377.867.382.5112123117110115138172
Sales YoY Gr.-6.2%-13.5%22.6%35.2%10%-4.3%-6.1%4.8%19.4%-
Adj EPS -0.1-00.14.87.78.89.21011.41110.5
YoY Gr.-NANA4650%62.5%14.1%4.8%7.8%14.3%-2.9%-
BVPS (₹) 18.317.817.924.763.773.798.6104.5114.8147.7159.1
Adj Net
Profit
-0.100.15910.311.312.213.91413
Cash Flow from Ops. 5.1-3.36.23.6-5.54.311.7134.8-3.5-
Debt/CF from Ops. 3-6.33.34.9-2.72.711.55.4-7.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 7.3%4.3%5.5%19.4%
Adj EPS NA7.4%6.2%-2.9%
BVPS26.1%18.3%14.4%28.6%
Share Price 47.5% 3.3% -7.9% -32.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
-0.5-0.20.622.417.812.810.89.59.88.26.8
Op. Profit
Mgn %
7.16.58.214.115.114.315.518.220.917.915.1
Net Profit
Mgn %
-0.1-0.10.26.18.18.49.6111210.17.7
Debt to
Equity
11.21.10.70.20.10.10.20.20.10
Working Cap
Days
198201230197196235287310332358165
Cash Conv.
Cycle
38424237647471668812876

Recent Performance Summary

Sales growth is good in last 4 quarters at 25.09%

Return on Equity has declined versus last 3 years average to 6.80%

Sales growth has been subdued in last 3 years 5.52%

Net Profit has been subdued in last 3 years 6.15%

Latest Financials - Medicamen Biotech Ltd.

Standalone Consolidated
TTM EPS (₹) 10.5 8.6
TTM Sales (₹ Cr.) 172 179
BVPS (₹.) 159.1 152.1
Reserves (₹ Cr.) 196 188
P/BV 3.08 3.22
PE 46.83 56.97
From the Market
52 Week Low / High (₹) 356.75 / 903.50
All Time Low / High (₹) 2.25 / 1219.00
Market Cap (₹ Cr.) 623
Equity (₹ Cr.) 12.7
Face Value (₹) 10
Industry PE 43.9

Management X-Ray of Medicamen Biotech:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Medicamen Biotech

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales73786782112123117110115138
Operating Expenses 6873627195105999091113
Manufacturing Costs20212019302225292433
Material Costs35372937496960474453
Employee Cost 555798991519
Other Costs 9988765599
Operating Profit 55612171718202425
Operating Profit Margin (%) 7.1%6.5%8.2%14.0%15.1%14.2%15.4%18.2%20.9%17.9%
Other Income 1110242122
Interest 4444311223
Depreciation 2222222366
Exceptional Items 0000000000
Profit Before Tax 0016141817171817
Tax 0001454432
Profit After Tax 0005101212121515
PAT Margin (%) 0.1%0.6%0.7%6.3%9.1%9.8%10.4%11.3%12.9%10.9%
Adjusted EPS (₹)0.10.50.54.98.610.310.010.212.211.9
Dividend Payout Ratio (%)0%0%0%0%12%10%5%10%8%8%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 161718267587122134148194
Share Capital 9101011121212121213
Reserves 778156375110122136181
Minority Interest0000000000
Debt15201817141210172424
Long Term Debt0542002651
Short Term Debt1516151414128111923
Trade Payables24271922223132304246
Others Liabilities 95597812111111
Total Liabilities 65696073118137176192225275

Fixed Assets

Gross Block34353638464758116124130
Accumulated Depreciation13151719202224263238
Net Fixed Assets22201919252434909292
CWIP 100001540000
Investments 0000002224
Inventories1313111414151752745
Trade Receivables20271626384344506160
Cash Equivalents 323323923420
Others Assets671111173037433953
Total Assets 65696073118137176192225275

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 5-364-5412135-3
PBT 0006141717171817
Adjustment 5455423379
Changes in Working Capital 1-81-8-23-11-3-3-17-26
Tax Paid 0000-1-4-4-4-3-3
Cash Flow From Investing Activity -10-1-2-8-15-39-18-8-8
Capex -10-1-2-8-16-38-18-9-6
Net Investments 000000-200-2
Others 0000010001
Cash Flow From Financing Activity -43-5-133-4216428
Net Proceeds from Shares 0113390250031
Net Proceeds from Borrowing 04-1-1-2024-1-4
Interest Paid -3-3-3-3-2-1-1-1-1-3
Dividend Paid 0000-10-1-1-1-1
Others -10-100-3-4385
Net Cash Flow 100020-14-61117
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)0.592.662.7623.520.1214.9611.8610.0611.129.17
ROCE (%)13.0911.5811.3624.124.9120.2215.2613.1212.8210.95
Asset Turnover Ratio1.131.171.051.241.170.960.750.60.550.55
PAT to CFO Conversion(x)N/AN/AN/A0.8-0.50.3311.080.33-0.2
Working Capital Days
Receivable Days9611011592105122136155175161
Inventory Days69626755464450375195
Payable Days241250284200164138191237299302

Medicamen Biotech Ltd Stock News

Medicamen Biotech Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Medicamen Biotech on 12-Jul-2024 16:01 is ₹484.6.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Jul-2024 16:01 the market cap of Medicamen Biotech stood at ₹622.8.
The latest P/E ratio of Medicamen Biotech as of 12-Jul-2024 16:01 is 46.83.
The latest P/B ratio of Medicamen Biotech as of 12-Jul-2024 16:01 is 3.08.
The 52-week high of Medicamen Biotech is ₹903.5 and the 52-week low is ₹356.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Medicamen Biotech is ₹172.4 ( Cr.) .

About Medicamen Biotech Ltd

Medicamen Biotech Limited was incorporated in December 1993, it is a widely held, Globaly Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. Medicamen Biotech Limited is committed to produce and provide quality medicines at competitive price for domestic as well as international markets thereby being socially responsible and rendering services to the medical fraternity since inception.

Medicamen Biotech started its operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries.The vast distribution network with demand for low cost medicines prompted Mr. B.K. Gupta - Managing Director of the company to go for own manufacturing facilities. Thus in the later part of 1994 a land of 2,10,000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured.

In 1995 Medicamen Biotech Limited was enlisted in Bombay Stock Exchange and public issue was oversubscribed by more than 11 times. Within a span of 10 years Medicamen Biotech Limited is now among top 50 Indian export company.

In the year 2005 keeping the pace with the ever increasing demand and fulfilling the commitment, a second unit was installed in the Tax free zone at Haridwar in the state of Uttarakhand .The Unit II is fully operational from April 2007 with ultra modern manufacturing facilities.

Product range of the company includes:

The company is the Manufacturer and supplier of Comprehensive range of products:

  • Tablets
  • Capsules
  • Liquid Syrup
  • Dry Syrup (Beta Lactum and Non Beta Lactum)
  • Ointment
  • ORS

Achievements/ recognition:

The company is the receipents of the following certificates & awards:

  • WHO-GMP
  • ISO 9001: 2000
  • Star Export House
  • Certificate Of Merit
  • “Niryat Shree” for the four consecutive years from 2002 to 2005 from Government of India
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.